Segment Wealth Management LLC Boosts Stock Position in Stryker Corporation (NYSE:SYK)

Segment Wealth Management LLC increased its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 1.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,476 shares of the medical technology company's stock after acquiring an additional 682 shares during the period. Stryker comprises 1.3% of Segment Wealth Management LLC's holdings, making the stock its 17th largest position. Segment Wealth Management LLC's holdings in Stryker were worth $19,534,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Elefante Mark B purchased a new position in shares of Stryker during the 4th quarter valued at approximately $337,000. Mogy Joel R Investment Counsel Inc. grew its position in Stryker by 3.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock valued at $36,561,000 after buying an additional 3,218 shares during the period. Ferguson Wellman Capital Management Inc. increased its holdings in Stryker by 1.9% in the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock valued at $65,096,000 after buying an additional 3,341 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new position in shares of Stryker in the first quarter worth about $1,840,000. Finally, Metis Global Partners LLC boosted its stake in shares of Stryker by 10.2% during the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after acquiring an additional 1,561 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Up 0.6%

NYSE SYK traded up $2.18 on Friday, reaching $375.44. 2,014,462 shares of the company were exchanged, compared to its average volume of 1,336,285. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69. The business's fifty day moving average price is $374.45 and its 200 day moving average price is $375.41. The stock has a market capitalization of $143.30 billion, a P/E ratio of 50.73, a price-to-earnings-growth ratio of 2.81 and a beta of 0.91. Stryker Corporation has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.50 EPS. Analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's payout ratio is 45.41%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SYK shares. Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. BTIG Research set a $403.00 price objective on Stryker and gave the company a "buy" rating in a research report on Monday, April 14th. Citigroup reaffirmed a "buy" rating and set a $455.00 target price (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. JMP Securities reissued a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Finally, Roth Mkm upped their price objective on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Stryker presently has an average rating of "Moderate Buy" and a consensus target price of $427.30.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.